About GSK

We are a science-led global healthcare company with a special purpose to improve the quality of human life by helping people do more, feel better, live longer.

£34.1bn
Group turnover in 2021
3
global businesses
300
years of innovation

What we do

We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, preventing and treating disease and keeping people well with our scientific and technical know-how and talented people.

Pharmaceuticals
Vaccines
Consumer Healthcare

Pharmaceuticals

Immune system T-cells attacking a cancer cell

£17.7bn, +10% CER sales turnover 2021

Our Pharmaceuticals business has a broad portfolio of innovative and established medicines in respiratory, HIV, immuno-inflammation and oncology. We are strengthening our R&D pipeline through a focus on immunology, human genetics and advanced technologies to help us deliver transformational new medicines for patients.

Key products
Trelegy – Asthma/COPD
Nucala – Severe Asthma
Triumeq/Tivicay – HIV

Vaccines

£6.8bn, +2% CER sales turnover 2021

We are the world’s largest vaccines company by revenue, delivering vaccines that help protect people at all stages of life. Our R&D focuses on developing vaccines against infectious diseases that combine high medical need and strong market potential.

Key products
Shingrix – Shingles
Infanrix – Paediatric
Bexsero – Meningitis

Consumer Healthcare

Novamin, a key technology in Sensodyne Repair and Protect

£9.6bn, stable CER sales turnover 2021 (+4% excluding brands divested/under review)

Our world-leading Consumer Healthcare business combines science and consumer insights to create innovative everyday healthcare brands that consumers trust and experts recommend for oral health, pain relief, cold, flu and allergy, digestive health and vitamins, minerals and supplements.

In early 2020, we started a two-year programme to prepare GSK for separation into two new, exciting companies - a new GSK in Biopharma and a new world leader in Consumer Healthcare. We remain on track to separate in 2022.

Key products
Sensodyne – Oral health
Voltaren – Pain relief (topical)
Panadol – Pain relief (systemic)

How we do it

Everyone at GSK is focused on our three long-term priorities - Innovation, Performance, Trust - underpinned by our ambition to build a more purpose and performance driven culture, aligned to our values.

Innovation
Performance
Trust

Innovation

We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers and consumers.

£4.8bn
adjusted R&D investment in 2021
43
new medicines in development at FY 2021
21
new vaccines in development at FY 2021

Performance

We deliver growth by investing effectively in our business, developing our people and executing competitively.

£34.1bn
Group turnover in 2021
£8.8bn
adjusted operating profit in 2021
£4.4bn
free cash flow in 2021
£4bn
dividends paid in 2021

Trust

We are a responsible company. We commit to use our science and technology to address health needs, make our products affordable and available and be a modern employer.